Cue Biopharma, Inc. Deferred Revenue Recognized
Cue Biopharma, Inc. (CUE) had Deferred Revenue Recognized of $3.00 million as of 2021-11-23, per its 10-K filed 2025-03-31.
Financial Statements › Notes
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2025-03-31
- 2021-11-23: Contract with Customer, Liability, Revenue Recognized $3.00M.
- 2020-12-07: Contract with Customer, Liability, Revenue Recognized $1.25M.
- 2019-05-16: Contract with Customer, Liability, Revenue Recognized $2.50M.
| Period end | Contract with Customer, Liability, Revenue Recognized |
|---|---|
| 2021-11-23 | $3.00M 10-K · filed 2025-03-31 |
| 2020-12-07 | $1.25M 10-K · filed 2025-03-31 |
| 2019-05-16 | $2.50M 10-K · filed 2025-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |